Type of preexisting lipid therapy predicts LDL-C response to ezetimibe. - Wikidata - awgldk - TriplyDB

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

http://www.wikidata.org/entity/Q33241121

about

Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.

P2860

Q36653658-25782D6A-DE90-410B-A1EC-CC1A62428C6E

P2860

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

http://www.wikidata.org/entity/Q33241121

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

@ast

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

@en

type

label

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

@ast

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

@en

prefLabel

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

@ast

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

@en

P1433

Q33241121-7E194C3E-5E38-43A8-88F9-01BCFDB86939

P1476

Q33241121-8D2E1567-60BC-4AA6-88E9-AFFAC2A50EF8

P2093

Q33241121-3DE72F78-F781-4FD6-B043-0E281CDF4F86

Q33241121-578AC741-B010-4E12-9020-A5A28E327FAC

Q33241121-8F799166-283C-4AFB-BA1C-F7BAA9312EE1

Q33241121-95E144A9-8C00-4D0A-A0BD-919D3F483265

P2860

Q33241121-0B66CC8B-C87F-45A4-BA6B-1EA6FABC6AF8

Q33241121-2A3DEE8D-D5C7-478F-AA35-DC61F64C694B

Q33241121-33761F09-E11B-4A73-998D-DE2EED4F150D

Q33241121-359BD47A-2E02-43C9-A7D5-7A9A8AFAC39D

Q33241121-4DE9880A-3C42-4B28-B6FB-1114471A6501

Q33241121-63E9A76D-6813-4366-ABA3-06D15A4A8FD4

Q33241121-6C8C1913-826F-44AD-AEF8-4446AC29597A

Q33241121-6E1F1308-927E-4DE4-B2A5-E2BC61E25B39

Q33241121-86D5BB8D-869D-4A43-972A-E291575A72F0

Q33241121-A3CCCE18-7A82-4024-90AE-1868E6FD7072

P304

Q33241121-373FE797-AE03-4397-BBD8-7615E9C654EE

P31

Q33241121-6E63086F-6FB2-4F9F-992F-4F34BF1006E3

P356

Q33241121-8609D0BE-9221-4EC8-B5C5-393C7CF11BAB

P407

Q33241121-DC0DB1DF-82D4-4A9F-99E5-69BF342C5214

P433

Q33241121-69050BBA-67FD-4DCD-94C7-7E3A0E1A0965

P478

Q33241121-96077CEA-416A-42A4-8F5E-D44695900903

P577

Q33241121-F6FAAD65-C9ED-4BE7-85FB-081078DC7B5C

P5875

Q33241121-8A3877C8-9F83-4F4F-B164-706D80014126

P698

Q33241121-47B79974-7D81-45DE-9F91-511F9F40B3D6

P356

P1433

Annals of Pharmacotherapy

P1476

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.

@en

P2093

Charles D Meyers

http://www.w3.org/2001/XMLSchema#string

Hoda Ghanem

http://www.w3.org/2001/XMLSchema#string

Nathan D Wong

http://www.w3.org/2001/XMLSchema#string

Yong S K Moon

http://www.w3.org/2001/XMLSchema#string

P2860

NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia.

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.

Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment.

P304

818-823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1G639

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7141990

http://www.w3.org/2001/XMLSchema#string

P698

16638916

http://www.w3.org/2001/XMLSchema#string